Table 2 HQ-CT Change from Baseline at Week 26 Subgroup Analyses Comparing C601/C602 Cohort to PATH for PWS Cohort
Number of participants | LS Mean (95% CI) | LS Mean Difference (95% CI)* | P-value | |||
|---|---|---|---|---|---|---|
Subgroup | C601/ C602 | PATH | C601/C602 | PATH | ||
Age | ||||||
< 18 | 91 | 129 | -8.7 (-10.1, -7.3) | -3.0 (-4.2, -1.8) | -5.7 (-7.6, -3.8) | < 0.001 |
≥ 18 | 17 | 100 | -7.4 (-10.1, -4.7) | -1.5 (-2.6, -0.3) | -6.0 (-8.9, -3.0) | < 0.001 |
Sex | ||||||
Female | 63 | 119 | -8.2 (-9.8, -6.6) | -2.9 (-4.1, -1.8) | -5.3 (-7.4, -3.3) | < 0.001 |
Male | 45 | 110 | -8.5 (-10.4, -6.5) | -1.8 (-3.1, -0.6) | -6.6 (-9.0, -4.3) | < 0.001 |
PWS Subtype | ||||||
Deletion | 69 | 113 | -9.2 (-10.8, -7.7) | -2.1 (-3.3, -0.9) | -7.1 (-9.1, -5.1) | < 0.001 |
Non-Deletion | 39 | 82 | -7.2 (-9.4, -5.0) | -2.8 (-4.3, -1.4) | -4.3 (-7.1, -1.6) | 0.002 |
Growth Hormone Use | ||||||
Both Visits | 93 | 130 | -8.6 (-10.1, -7.2) | -2.8 (-4.0, -1.6) | -5.8 (-7.7, -3.9) | < 0.001 |
Untreated | 15 | 87 | -6.8 (-9.8, -3.8) | -1.9 (-3.1, -0.6) | -4.9 (-8.2, -1.7) | 0.004 |
Region | ||||||
United States | 86 | 202 | -9.2 (-10.6, -7.8) | -2.6 (-3.4, -1.7) | -6.6 (-8.3. -5.0) | < 0.001 |
Ex-United States | 22 | 27 | -5.4 (-8.3, -2.4) | -0.8 (-3.5, 1.8) | -4.5 (-8.6, -0.5) | 0.028 |
Baseline HQ-CT | ||||||
Above Median (≥ 18) | 75 | 103 | -10.7 (-12.3, -9.1) | -2.6 (-3.9, -1.2) | -8.1 (-10.3, -6.0) | < 0.001 |
Below Median (< 18) | 33 | 126 | -4.4 (-6.3, -2.5) | -1.8 (-2.8, -0.9) | -2.6 (-4.7, -0.4) | 0.019 |